Tiotropium Inhalation Powder Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalable powders for tiotropium have challenges with accurate metering, homogeneity, and emptying characteristics, leading to variability in the delivery of the active substance to the lungs, which affects the therapeutic efficacy and requires complex manufacturing processes.
Innovation Solution
Inhalable powders with tiotropium are formulated using a physiologically acceptable excipient with a specific particle size range (10-50 μm) and fine content (0.5-6 μm) and specific surface area (0.1-2 m2/g), combined with tiotropium bromide monohydrate, to ensure accurate metering, high homogeneity, and improved emptying characteristics, using conventional milling and sieving methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If finer excipient is used to improve the inhalable proportion of active substance, then the particle size is reduced for better lung delivery, but the flow properties deteriorate
Solution Approach 1:
The patent applies parameter changes by precisely controlling the particle size distribution of the excipient within specific ranges (D10: 3-8 μm, D50: 10-20 μm, D90: 15-30 μm) and adjusting the specific surface area (0.5-2.0 m²/g). This optimization balances the inhalable proportion with flow properties, allowing fine particles for lung delivery while maintaining adequate flow through controlled size distribution and surface characteristics.
Solution Approach 2:
The patent uses composite material principles by creating a powder mixture containing tiotropium bromide (0.01-1% w/w) combined with excipient having specific particle size characteristics. The composite formulation integrates the active substance with carefully selected excipient properties to achieve both high inhalable proportion and acceptable flow properties through synergistic combination.
2Quantity of substance
If higher concentration of active substance is used to ensure therapeutic effect, then the dosage is increased, but the homogeneity of powder mixture deteriorates
Solution Approach 1:
The patent optimizes the concentration of tiotropium bromide within a specific range (0.01-1% w/w) and controls the particle size of the active substance (D50: 2-5 μm, D90: <10 μm). By adjusting these parameters, the formulation achieves therapeutic efficacy while maintaining homogeneous distribution in the powder mixture, preventing segregation and ensuring consistent dosing.
3Manufacturing precision
If complex manufacturing processes are used to achieve accurate metering, then the metering precision is improved, but the device complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the excipient particle size distribution and specific surface area before mixing with the active substance. This preliminary characterization and preparation of the excipient ensures that subsequent mixing and metering processes achieve accurate dosing with conventional equipment, eliminating the need for complex manufacturing processes.
4Quantity of substance
If more excipient is used to dilute the active substance, then the powder quantity is increased for inhalable formulation, but the specific surface area increases leading to poorer flow
Solution Approach 1:
The patent controls the specific surface area of the excipient within a optimized range (0.5-2.0 m²/g) while maintaining the particle size distribution (D10: 3-8 μm, D50: 10-20 μm, D90: 15-30 μm). This parameter optimization allows sufficient powder quantity for effective dilution of the active substance while preventing excessive specific surface area that would degrade flow properties.
Data Source
AI summary
The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.